

## Special Issue

# New Paradigm of Gene Therapy

### Message from the Guest Editor

Gene therapy is defined as introducing genetic information for therapeutic purposes. Besides conventional usage, such as protein-replacement therapies, in many medical fields, the applications have been widely expanding from vaccination against infectious diseases or cancer, and “gene” editing using the cutting-edge technologies of ZFN, TALENs, and CRISPR–Cas9. Cell therapy combined with ex vivo gene introduction is also an exciting field. The Special Issue of *Pharmaceutics* on “New paradigm of gene therapy” will address diverse areas related to gene therapy, including nucleic acids preparation (DNA, RNA), delivery systems, administration technique, and proof-of-concept studies using animal models. Original research papers or review articles on any of these aspects are welcomed for this Special Issue. Keiji Itaka

### Guest Editor

Prof. Dr. Keiji Itaka

1. Department of Biofunction Research, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Tokyo 101-0062, Japan
2. Clinical Biotechnology Team, Center for Infectious Disease Education and Research (CiDER), Osaka University, 1-1 Yamadaoka, Suita, Osaka 565-0871, Japan

### Deadline for manuscript submissions

closed (31 May 2015)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/4113](https://mdpi.com/si/4113)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).